Characterization of a selective and potent antagonist of human P2X<sub>7</sub>receptors, AZ11645373
Leanne Stokes(University of East Anglia), Annmarie Surprenant(University of Manchester), Jill Theaker(AstraZeneca (United Kingdom)), Martin Braddock(Multiconsult (Norway)), Mandy Lawson(AstraZeneca (United Kingdom)), Julian Bent(University of Leeds), Katherine Bowers(AstraZeneca (United Kingdom)), Michael Mortimore(AstraZeneca (United Kingdom)), Lindsay B. Alcaraz(AstraZeneca (United Kingdom)), Malbinder S. Fagura(AstraZeneca (United Kingdom)), Mark Furber(AstraZeneca (United Kingdom))
Cited by 131
Related Papers
The Cytolytic P <sub>2Z</sub> Receptor for Extracellular ATP Identified as a P <sub>2X</sub> Receptor (P2X <sub>7</sub> )
|Science|1996|1.7k
Pannexin‐1 mediates large pore formation and interleukin‐1β release by the ATP‐gated P2X7 receptor
|The EMBO Journal|2006|1.4k
A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP
|Nature|1994|1k
Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons
|Nature|1995|1k
Cloning OF P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels
|Journal of Neuroscience|1996|879